

News Release

No.23009
April 13, 2023
Noil-Immune Biotech, Inc
<https://www.noile-immune.com>

Publication of Research Papers on CAR-T Cells with Our Platform-based Technologies

Noile-Immune Biotech, Inc. (1-12-10 Shiba-Daimon, Minato-ku, Tokyo, President: Koji Tamada) has acquired an exclusive license of PRIME technology from Yamaguchi University. We are pleased to announce that a paper on the results of the joint research between Yamaguchi University and Noile-Immune Biotech, Inc. has been published in the electronic edition of Cancer Medicine, an international scientific journal.

- Paper Title: Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model
- Journal title: Cancer Medicine
- Author Name: Takahiro Sasaki, Yukimi Sakoda, Keishi Adachi, Yoshihiro Tokunaga, Koji Tamada
- DOI: 10.1002/cam4.5907
- Pubmed URL: <https://pubmed.ncbi.nlm.nih.gov/37031457/>
- Outline of the paper:
 - ① GM2, which is highly expressed in a variety of solid tumors, is a potential therapeutic target for PRIME CAR-T cell therapy.
 - ② PRIME CAR-T cells targeting GM2 demonstrated therapeutic efficacy against solid tumors in a preclinical model without adverse events.
 - ③ In vivo kinetics of PRIME CAR-T cells was regulated by introducing HSV-TK suicide gene.

Noile-Immune Biotech Inc., established as a university start-up, aims to contribute to the arrival of an era when we can overcome cancer through the next-generation cancer immunotherapies, centering on PRIME technology.

Contact for inquiries or additional information
2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan
Noile-Immune Biotech, Inc.
Department of Administration
E-mail: ir@noile-immune.com